Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Akeso

Tracked across 4 events · 52 articles · First seen May 25, 2026 · Last active Sep 13, 2026

Sentiment
64
Attention
7
Events
4
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 80
Business
Impact: Akeso received NMPA approval for Gumokimab, strengthening its autoimmune disease portfolio and global competitiveness. This approval is a significant milestone for the company, enhancing its market position and offering a new treatment option for psoriasis patients.
Jun 12, 2026 · 7 articles
4 40
Tech
Impact: Akeso is the developer and sponsor of the Phase II study, and this milestone advances its IO2.0 + ADC2.0 strategy. The company's pipeline and clinical progress are central to its valuation and growth prospects.
Aug 10, 2026 · 6 articles
4 70
Tech
Akeso announced that a pre-specified interim analysis of overall survival (OS) in the Phase III HARMONi-2 (AK112-303) trial, assessed by the Independent Data Monitoring Committee, met the key secondary OS endpoint. Ivonescimab, Akeso's first-in-class PD-1/VEGF…
Impact: Akeso is the sponsor and primary beneficiary of the HARMONi-2 trial; the positive OS results reinforce ivonescimab's best-in-class potential and support its commercial and licensing outlook.
Jul 20, 2026 · 6 articles
7 65
Tech
Impact: Akeso announced that over 40 clinical studies of its oncology portfolio, including data on cadonilimab and ivonescimab, were presented at the 2026 ASCO Annual Meeting, with one Late-Breaking Abstract selected for a Plenary Session.
May 25, 2026 · 33 articles
95 Akeso met overall survival endpointIvonescimab HARMONi-2...
85 Akeso presented overall survival resultsIvonescimab HARMONi-2...
60 Akeso met progression-free survival endpointIvonescimab HARMONi-2...
55 China approved ivonescimab indication AkesoIvonescimab HARMONi-2...
ERGEN INTELLIGENCE
Track Akeso live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.